- Home
- ARQT vs ARWR Comparison
ARQT vs ARWR Comparison
Compare ARQT & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- ARWR
- Stock Information
- Founded
- ARQT 2016
- ARWR 2003
- Country
- ARQT United States
- ARWR United States
- Employees
- ARQT N/A
- ARWR N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- ARQT Health Care
- ARWR Health Care
- Exchange
- ARQT Nasdaq
- ARWR Nasdaq
- Market Cap
- ARQT 1.7B
- ARWR 1.8B
- IPO Year
- ARQT 2020
- ARWR 1993
- Fundamental
- Price
- ARQT $14.29
- ARWR $15.93
- Analyst Decision
- ARQT Strong Buy
- ARWR Buy
- Analyst Count
- ARQT 7
- ARWR 8
- Target Price
- ARQT $18.67
- ARWR $43.71
- AVG Volume (30 Days)
- ARQT 1.5M
- ARWR 2.1M
- Earning Date
- ARQT 08-06-2025
- ARWR 08-07-2025
- Dividend Yield
- ARQT N/A
- ARWR N/A
- EPS Growth
- ARQT N/A
- ARWR N/A
- EPS
- ARQT N/A
- ARWR N/A
- Revenue
- ARQT $212,819,000.00
- ARWR $545,209,000.00
- Revenue This Year
- ARQT $61.83
- ARWR $22,384.93
- Revenue Next Year
- ARQT $36.55
- ARWR N/A
- P/E Ratio
- ARQT N/A
- ARWR N/A
- Revenue Growth
- ARQT 100.03
- ARWR 1436.97
- 52 Week Low
- ARQT $7.86
- ARWR $9.57
- 52 Week High
- ARQT $17.75
- ARWR $28.72
- Technical
- Relative Strength Index (RSI)
- ARQT 46.02
- ARWR 46.71
- Support Level
- ARQT $14.44
- ARWR $15.51
- Resistance Level
- ARQT $15.38
- ARWR $16.69
- Average True Range (ATR)
- ARQT 0.66
- ARWR 1.11
- MACD
- ARQT -0.09
- ARWR -0.17
- Stochastic Oscillator
- ARQT 10.19
- ARWR 32.44
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.